Skip to main content
. 2019 Jan 8;6(2):336–343. doi: 10.1002/ehf2.12390

Figure 2.

Figure 2

Distribution of plasma xanthine oxidoreductase (XOR) activity in each group. (A) In the control group, the plasma XOR activity was <25 pmol/h/mL in 71 (30.7%) patients and >300 pmol/h/mL in seven (3.0%). (B) In the acute heart failure (AHF) group, the plasma XOR activity was <25 pmol/h/mL in 29 (24.6%) patients and >300 pmol/h/mL in 34 (28.8%).